PubMed Health⌕ Search

Biomedical subjects

D J Torgerson

Publications and source records attributed to D J Torgerson.

At least 19 recordsLinked to original sources
PubMed1999

Bootstrapping: estimating confidence intervals for cost-effectiveness ratios.

Economic evaluations are increasingly being conducted alongside clinical trials of health interventions, with resource consequences being estimated from stochastic data. It is, therefore, important that economic evaluation results, like the clinical results, reflect the underlying variance within the sample data. A statistical methodology, known as bootstrapping, has recently been put forward as a potential method for calculating confidence intervals for cost-effectiveness ratios, yet it is still unusual to see economic evaluations reporting confidence intervals. In this paper we demonstrate the practical application of bootstrapping using real data from clinical trials, and conclude that bootstrapping is easily transferable from theory to practice for the estimation of confidence intervals for cost-effectiveness ratios. We encourage further investigation into its applicability and use.

Confidence Intervals↗
PubMed1998

Direct disclosure of bone density results to patients: effect on knowledge of osteoporosis risk and anxiety level.

If bone mineral density (BMD) screening is to achieve the aim of preventing the complications of osteoporosis, women with low BMD measurements must learn that they are at risk, and women at risk must know about and be willing to adopt and persist with measures that can prevent osteoporosis. In this paper we present the results of a randomized controlled trial designed to examine whether disclosing the results of a BMD scan directly to women, as well as through their general practitioners (GPs), improves their knowledge of their bone density results without adverse psychological sequelae. Direct disclosure resulted in 19% (59% vs 40%; 95% CI for difference in proportions: 9.8% to 27.8%) more women being aware of their BMD status at the spine and 22% (58% vs 36%; 95% CI for difference: 12.2% to 29.8%) at the hip. These differences were observed irrespective of risk status. There was no significant difference in anxiety levels between the randomized groups. We conclude, therefore, that direct disclosure of BMD results to women, as well as to their GPs, leads to increased knowledge of BMD status without increasing anxiety, and that BMD measurement services should consider informing women routinely of their results directly as well as through their GPs.

Anxiety↗
PubMed1998

The cost of treating osteoporotic fractures in the United Kingdom female population.

Osteoporotic fractures represent a significant burden to society. The costs of osteoporotic fractures to the UK health care system have not previously been accurately described. In this paper, we quantify the health care and social care costs of fractures occurring in women aged 50 years and over in the UK. We used a variety of data sources. For acute hospital hip fracture costs existing published estimates were used whilst for social care costs a survey of resource use among fracture patients before and after hip fracture was utilized. We undertook a case-control study using the General Practice Research Database to estimate primary care costs. From these data we estimated that the cost of a hip fracture is about 12,000 Pounds, with non-acute hospital costs representing the larger proportion. The other fractures were less expensive, at 468 Pounds, 479 Pounds and 1338 Pounds for wrist, vertebral and other fractures, respectively. For all fractures the annual cost to the UK is 727 million Pounds. Assuming each male hip fracture costs the same as a female fracture, including these would increase the total costs to 942 million Pounds.

Aged↗
PubMed1998

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

In the UK, over 250 000 patients take continuous oral glucocorticoids (GCs), yet no more than 14% receive any therapy to prevent bone loss, a major complication of GC treatment. Bone loss is rapid, particularly in the first year, and fracture risk may double. This review, based wherever possible on clinical evidence, aims to provide easy-to-use guidance with wide applicability. A treatment algorithm is presented for adults receiving GC doses of 7.5 mg day(-1) or more for 6 months or more. General measures, e.g. alternative GCs and routes of administration, and therapeutic interventions, e.g. cyclical etidronate and hormone replacement, are recommended.

Bone Resorption↗
PubMed1998

Prescribing by general practitioners after an osteoporotic fracture.

OBJECTIVES: Osteoporosis is a major cause of morbidity and cost. Patients sustaining one osteoporotic fracture are at increased risk of having another fracture. The objective of this study was to examine the use of "bone drugs" for the prevention of further osteoporotic fractures among patients who have had a "typical" osteoporotic fracture. METHODS: This study took a random sample of 300 women aged 50 and over who had sustained either a vertebral, hip or Colles fracture in 1995 from the General Practice Research Database (GPRD) and compared their use of bone drugs with 300 age and practice matched controls. RESULTS: Compared with age and practice matched control patients only vertebral fracture patients showed a statistically significant increase in the use of bone drugs in the year after fracture (39% and 2% for cases and controls respectively; 95% CI of difference 27% to 47%). Etidronate was the most commonly used compound. CONCLUSION: The majority of patients sustaining an osteoporotic fracture are not prescribed any pharmaceutical agents for the secondary prevention of fracture one year after a primary fracture.

Aged↗
PubMed1997

Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results.

BACKGROUND: Screening perimenopausal women for low bone density has yet to be tested in a randomized trial. The effect of screening on the use of hormone replacement therapy (HRT) and the subsequent quality of life in these women is unknown. The purpose of this study was to assess the effect of a screening program on HRT use of quality of life. METHODS: A random sample of women aged 45 to 54 years and living within 32 km of Aberdeen, Scotland, was selected from the community health index. Subjects were further randomized to screening or no screening using the design of Zelen. Two years after randomization, a questionnaire follow-up was mailed to both groups to assess HRT use and quality-of-life scores. RESULTS: Use of HRT was higher in the screened group (30% vs 24%; difference, 6%; 95% confidence interval, 1%-11%; P = .02). A multivariate analysis indicated that the odds of using HRT for a screened woman whose measurement for bone mineral density was in the lowest quartile was 2.54 (95% confidence interval, 1.74-3.71) greater than that of an unscreened woman. Screening and subsequent HRT use did not have any detectable effects-positive or adverse-on women's quality of life. CONCLUSION: Screening for low bone density significantly increases the use of HRT in this population but without any immediate adverse or positive effects on quality of life.

Bone Density↗
PubMed1997

Should we pay the patient? Review of financial incentives to enhance patient compliance.

OBJECTIVE: To determine whether financial incentives increase patients' compliance with healthcare treatments. DATA SOURCES: Systematic literature review of computer databases--Medline, Embase, PsychLit, EconLit, and the Cochrane Database of Clinical Trials. In addition, the reference list of each retrieved article was reviewed and relevant citations retrieved. STUDY SELECTION: Only randomised trials with quantitative data concerning the effect, of financial incentives (cash, vouchers, lottery tickets, or gifts) on compliance with medication, medical advice, or medical appointments were included in the review. Eleven papers were identified as meeting the selection criteria. DATA EXTRACTION: Data on study populations, interventions, and outcomes were extracted and analysed using odds ratios and the number of patients needed to be treated to improve compliance by one patient. RESULTS: 10 of the 11 studies showed improvements in patient compliance with the use of financial incentives. CONCLUSIONS: Financial incentives can improve patient compliance.

Economics↗